Almotriptan adverse reactions: Difference between revisions
No edit summary |
No edit summary |
||
Line 36: | Line 36: | ||
Table 1 lists the adverse events that occurred in at least 1% of the adult patients treated with Almotriptan, and at an incidence greater than in patients treated with placebo, regardless of drug relationship. | Table 1 lists the adverse events that occurred in at least 1% of the adult patients treated with Almotriptan, and at an incidence greater than in patients treated with placebo, regardless of drug relationship. | ||
{| | |||
|- | |||
|[[Image:Incidence of Adverse Events in Controlled Clinical Trials (Reported in at Least 1% of Adult Patients Treated with AXERT®, and at an Incidence.PNG|thumb|400px]] | |||
|- | |||
|} | |||
The incidence of adverse events in controlled clinical trials was not affected by gender, weight, age, presence of aura, or use of prophylactic medications or oral contraceptives. There were insufficient data to assess the effect of race on the incidence of adverse events. | |||
Adolescents | |||
Table 2 lists the adverse reactions reported by 1% or more of Almotriptan-treated adolescents age 12 to 17 years in 1 placebo-controlled, double-blind clinical trial. | |||
==References== | ==References== |
Revision as of 04:28, 5 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Adverse Reactions
The most common adverse reactions (≥1% and greater than placebo) are:
- In adults: nausea, dry mouth and paresthesia
- In adolescents: dizziness, somnolence, headache, paresthesia, nausea and vomiting
Serious cardiac reactions, including myocardial infarction, have occurred following the use of Almotriptan (almotriptan malate) Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD. Reactions reported in association with triptans have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation [see Contraindications (4.1) and Warnings and Precautions (5.1)].
The following adverse reactions are discussed in more detail in other sections of the labeling:
Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events [see Warnings and Precautions (5.1)]
Sensations of Pain, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw [see Warnings and Precautions (5.2)]
Cerebrovascular Events and Fatalities [see Warnings and Precautions (5.3)]
Other Vasospasm-Related Events, Including Peripheral Vascular Ischemia and [see Colonic Ischemiaarnings and Precautions (5.4)]
Serotonin Syndrome [see Warnings and Precautions (5.5)]
Increases in Blood Pressure [see Warnings and Precautions (5.6)]
Adverse events were assessed in controlled clinical trials that included 1840 adult patients who received one or two doses of Almotriptan and 386 adult patients who received placebo. The most common adverse reactions during treatment with Almotriptan were nausea, somnolence, headache, paresthesia, and dry mouth. In long-term open-label studies where patients were allowed to treat multiple attacks for up to 1 year, 5% (63 out of 1347 patients) withdrew due to adverse experiences.
Adverse events were assessed in controlled clinical trials that included 362 adolescent patients who received Almotriptan and 172 adolescent patients who received placebo. The most common adverse reactions during treatment with Almotriptan were dizziness, somnolence, headache, paresthesia, nausea, and vomiting. In a long-term, open-label study where patients were allowed to treat multiple attacks for up to 1 year, 2% (10 out of 420 adolescent patients) withdrew due to adverse events.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Almotriptan Clinical Trials
Adults
Table 1 lists the adverse events that occurred in at least 1% of the adult patients treated with Almotriptan, and at an incidence greater than in patients treated with placebo, regardless of drug relationship.
The incidence of adverse events in controlled clinical trials was not affected by gender, weight, age, presence of aura, or use of prophylactic medications or oral contraceptives. There were insufficient data to assess the effect of race on the incidence of adverse events.
Adolescents
Table 2 lists the adverse reactions reported by 1% or more of Almotriptan-treated adolescents age 12 to 17 years in 1 placebo-controlled, double-blind clinical trial.